CN118159274A - 糖浆剂 - Google Patents

糖浆剂 Download PDF

Info

Publication number
CN118159274A
CN118159274A CN202280071476.7A CN202280071476A CN118159274A CN 118159274 A CN118159274 A CN 118159274A CN 202280071476 A CN202280071476 A CN 202280071476A CN 118159274 A CN118159274 A CN 118159274A
Authority
CN
China
Prior art keywords
syrup
salt
sodium
flavor
alectinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280071476.7A
Other languages
English (en)
Chinese (zh)
Inventor
加纳健雄
高桥翔大
前田有纪
桥本翔太
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN118159274A publication Critical patent/CN118159274A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280071476.7A 2021-10-28 2022-10-27 糖浆剂 Pending CN118159274A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021176595 2021-10-28
JP2021-176595 2021-10-28
PCT/JP2022/040113 WO2023074785A1 (ja) 2021-10-28 2022-10-27 シロップ剤

Publications (1)

Publication Number Publication Date
CN118159274A true CN118159274A (zh) 2024-06-07

Family

ID=86159947

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280071476.7A Pending CN118159274A (zh) 2021-10-28 2022-10-27 糖浆剂

Country Status (4)

Country Link
EP (1) EP4424313A4 (Home)
JP (1) JPWO2023074785A1 (Home)
CN (1) CN118159274A (Home)
WO (1) WO2023074785A1 (Home)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
WO2010143664A1 (ja) 2009-06-10 2010-12-16 中外製薬株式会社 4環性化合物
EP3698788A1 (en) * 2010-08-20 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Composition comprising tetracyclic compound
JP5006987B2 (ja) 2010-11-22 2012-08-22 中外製薬株式会社 4環性化合物を含む医薬
MX378186B (es) 2014-04-25 2025-03-10 Chugai Pharmaceutical Co Ltd Cristales novedosos de 9-etil-6,6-dimetil-8-(4-morfolin-4-il-piperidin-1-il)-11-oxo-6,11-dihidro-5h-benzo[b]carbazol-3-carbonitrilo.
TWI831128B (zh) 2014-04-25 2024-02-01 日商中外製藥股份有限公司 以高用量含有4環性化合物的製劑
TWI718102B (zh) 2014-08-08 2021-02-11 日商中外製藥股份有限公司 4環性化合物的非晶質體
EP3668515A4 (en) * 2017-08-18 2021-05-12 Abbvie Inc. PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ENDOMETRIOSIS, UTERINE FIBROMAS, POLYCYSTIC OVARY SYNDROME OR ADENOMYOSIS
IT201800001168A1 (it) * 2018-01-17 2019-07-17 Fond Per Listituto Oncologico Di Ricerca Ior Nuovi farmaci senolitici inibitori alk
WO2020004630A1 (ja) 2018-06-29 2020-01-02 中外製薬株式会社 難溶性の塩基性薬剤を含有する医薬組成物

Also Published As

Publication number Publication date
EP4424313A1 (en) 2024-09-04
EP4424313A4 (en) 2025-07-09
JPWO2023074785A1 (Home) 2023-05-04
WO2023074785A1 (ja) 2023-05-04

Similar Documents

Publication Publication Date Title
US20210228722A1 (en) Quinoline derivative-containing pharmaceutical composition
US12171768B2 (en) IRAK4 degraders and uses thereof
AU2014221630B2 (en) Suspension for oral administration comprising amorphous tolvaptan
JP7648698B2 (ja) 難溶性の塩基性薬剤を含有する医薬組成物
JP2022500505A (ja) トリヘキシフェニジルを含む徐放性組成物
JP2020518611A (ja) 水溶解度及びバイオアベイラビリティが改善された組成物
WO2015152680A1 (en) Granule comprising silodosin, and pharmaceutical composition and formulation comprising same
CN110013468A (zh) 一种azd9291氘代衍生物药物制剂
CN118159274A (zh) 糖浆剂
US20060034911A1 (en) New oral immediated release dosage form
WO2019230937A1 (ja) 溶出性に優れた経口固形製剤
CN105636580B (zh) 包含1-[6-(吗啉-4-基)嘧啶-4-基]-4-(1h-1,2,3-三唑-1-基)-1h-吡唑-5-醇钠的药物剂型
KR102308227B1 (ko) 수니티닙을 함유하는 경구용 정제 조성물
WO2018202224A1 (en) Film-coated tablets of deferasirox
JP2019073488A (ja) アプレピタントを有効成分とする医薬錠剤
WO2021136089A1 (zh) 一种抗肿瘤药物组合物以及提高化合物的溶解度的方法
JP6945377B2 (ja) エルロチニブを有効成分とする医薬錠剤及びその製造方法
CN107648237B (zh) 氨基嘧啶类化合物的药物组合物及其制备方法
TW202348231A (zh) 非晶形固體分散液及包含其之醫藥組合物
TW202432128A (zh) (R)-1-(1-丙烯醯基哌啶-3-基)-4-胺基-3-(4-苯氧基苯基)-1H-咪唑並[4,5-c]吡啶-2(3H)-酮之藥品調配物
HK40047994A (en) Pharmaceutical composition containing poorly soluble basic medicine
JP2019059685A (ja) エルロチニブを有効成分とする医薬錠剤
HK1225281B (zh) 包含1-[6-(嗎啉-4-基)嘧啶-4-基]-4-(1h-1,2,3-三唑-1-基)-1h-吡唑-5-醇鈉的藥物劑型

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40105554

Country of ref document: HK